Pressreleases

Medidata Solutions Further Extends Support for Industry Standards with Medidata Standards Accelerator

New solution facilitating study data tabulation model compliance enables clinical research sponsors to lower costs and reduce time to FDA submission

Synteract Achieves Study Build Accreditation in Medidata Solutions Channel Partner Program

Full-service CRO continues to increase global presence through Medidata Rave accreditation

LSK Global PS Joins Medidata Solutions Channel Partner Program

Second Korean Partner to Deliver Medidata Rave Study Build and Other Services to Local Sponsors in Preparation for KFDA Data Management Regulations

Biotech Companies Advancell, Neurotec Pharma and Aromics, Have Created the Consortium MSALS – in Order to Develop a New Treatment for Multiple Sclerosis

MSALS is funded through ACC1Ó’s Technological Innovation Nucleos programme, which provides assistance to projects being developed by groups of companies with diverse R&D, and is co-financed by the Catalan Regional Competitivity and Occupation Operational Programme 2007 – 2013, part of the European Regional Development Fund (FEDER).

Advancell Announces Promising Phase I/IIa Results with Acadra® in CLL

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a Phase I/IIa clinical study conducted with Acadra® in Chronic Lymphocytic Leukemia (CLL) patients resistant/refractory to current therapies. The company also announced promising non-clinical in vivo results with Acadra® in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra® in combination with current treatment in these indications has been demonstrated.

ADVANCELL Announces the Initiation of a Clinical Phase IIb Study of ATH008 in Hand-Foot Syndrome (or Palmar-PlantarErythrodysesthesia Syndrome)

Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.

Have You Got a ” B Plan” to Secure Your Development and R&D Programs?

We all know, that smart managers do not want to put all their eggs in the same basket. So why, with a success rate of less than 80% and declining, pharma top mangers do not systematically launch a "B plan" to secure their strategic R&D programs?

LSK Global PS Joins Medidata Solutions Channel Partner Program

Second Korean Partner to Deliver Medidata Rave Study Build and Other Services to Local Sponsors in Preparation for KFDA Data Management Regulations

Synteract Achieves Study Build Accreditation in Medidata Solutions Channel Partner Program

Full-service CRO continues to increase global presence through Medidata Rave accreditation